Jupiter Neurosciences Delays Annual 10-K Filing

Jupiter Neurosciences, Inc. ( (JUNS) ) has released a notification of late filing.

Jupiter Neurosciences, Inc. has filed a Form 12b-25 to notify investors of a delayed Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The company’s annual filing for this period, originally due March 31, 2026, is therefore being submitted after the standard deadline.

The primary reason for the delay is administrative rather than financial or operational. Management states that the Form 10-K (Yearly Report) was substantially completed, but the company missed the SEC’s 5:30 p.m. Eastern Time electronic filing cutoff and thus could not submit on time without unreasonable effort or expense.

Jupiter Neurosciences indicates that it is finalizing the documentation and expects to file the Form 10-K (Yearly Report) by April 1, 2026. Under the 12b-25 relief, the company has up to 15 calendar days after the prescribed due date for an annual report, and it has confirmed its intent to remain within this extended window.

The company does not anticipate any significant change in its results of operations compared with the prior fiscal year, based on the information to be included in the upcoming Form 10-K (Yearly Report). However, investors should note that any expectations about timing and financial outcomes remain forward-looking and could be affected by subsequent events or final audit conclusions.

Jupiter Neurosciences affirms that all other required periodic reports over the past 12 months have been filed, signaling an otherwise consistent compliance history. The notification is signed on behalf of the company by Chief Executive Officer Christer Rosén on April 1, 2026, underscoring management’s commitment to completing the annual reporting process and maintaining regulatory compliance.

The most recent analyst rating on (JUNS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Jupiter Neurosciences, Inc. stock, see the JUNS Stock Forecast page.

More about Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a U.S.-based biotechnology company focused on developing neuroscience-related therapies. It is listed as a registrant under the Securities Exchange Act of 1934 and files annual and periodic reports with the Securities and Exchange Commission. The company operates from its principal executive office in Jupiter, Florida.

Average Trading Volume: 320,831

Technical Sentiment Signal: Sell

Current Market Cap: $12.95M

For an in-depth examination of JUNS stock, go to TipRanks’ Overview page.